🔴 BreakingDrug approvalEMAYesterday
New medicine for two types of pulmonary fibrosis
The European Medicines Agency has approved a new medicine called Jascayd (nerandomilast) to treat adults with two types of lung scarring diseases: idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung disease. This approval means the medicine is now available for patients in the European Union. This is the first time this particular medicine has been approved for these conditions in Europe.
WHY IT MATTERSPatients with idiopathic pulmonary fibrosis in the EU now have access to a newly approved treatment option that may help slow lung scarring and preserve breathing ability.